[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354346-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354346-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","harnessing-skin-resident-t-cells-for-immunotherapy-in-cutaneous-squamous-cell-carcinoma","Harnessing skin-resident γδ T cells for immunotherapy in cutaneous squamous cell carcinoma","","Gamma delta (γδ) T cells are central to tissue immune surveillance, and their presence in tumors is linked to better outcomes, yet their skin-cancer potential has been limited by difficulties isolating enough γδ T cells from human tissue and the lack of suitable preclinical models. This study expands human cutaneous γδ T cells ex vivo and tests them in a human cutaneous squamous cell carcinoma xenograft mouse model. Recruited tumor-infiltrating cells show an activated, cytotoxic phenotype and strong in vivo antitumor activity, supporting skin-resident γδ T cells as a promising immunotherapy approach for cSCC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/harnessing-skin-resident-t-cells-for-immunotherapy-in-cutaneous-squamous-cell-carcinoma/354346/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/harnessing-skin-resident-t-cells-for-immunotherapy-in-cutaneous-squamous-cell-carcinoma/354346.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are γδ T cells considered promising for cancer immunotherapy?","Question",{"text":63,"@type":64},"γδ T cells support tissue immune surveillance, can act in an MHC-unrestricted manner, and rapidly induce cytotoxicity through multiple signaling pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What challenge limited research on γδ T-cell therapy in skin cancer?",{"text":68,"@type":64},"The limited ability to isolate sufficient numbers of γδ T cells from human tissues and the absence of suitable preclinical skin-cancer models restricted investigation.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the xenograft model show about cutaneous γδ T cells in cSCC?",{"text":72,"@type":64},"In the cSCC xenograft setting, γδ T cells are recruited and maintained, develop an activated cytotoxic phenotype, and demonstrate effective antitumor activity in vivo.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354346,1790852343,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":138,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},4398046744996,"CANCER  \nHarnessing skin-resident γδT cells for immunotherapy in cutaneous squamous cell carcinoma  \nGiorgia Nasi1*, Leonie C. Schöftner1,2, Lara Ronacher1, Amalia Sophianidis1, Julia Feiser1,2, Teodora Aleksandrova1,2, Oliver Nussbaumer3, Andrew Hutton4, Roland Zauner5, Johanna Moser-Waxenecker1, Suraj R. Varkhande1, Anshu Sharma1, Monika Ettinger6, Teresa Burner6, Martin Laimer7, Christina Guttmann-Gruber5, Iris K. Gratz1,2,8,9  \nGamma delta (γδ) T cells are critical for tissue immune surveillance and their presence in tumors correlates with a favorable prognosis, highlighting their therapeutic potential. Although γδ T cells are abundant in the skin, their therapeutic value in skin cancer has remained largely unexplored due to challenges in isolating sufficient numbers of γδ T cells from human tissues and a lack of suitable preclinical models for skin cancer. Here, we are using innovative methods to expand human cutaneous γδ T cells ex vivo, enabling us to investigate their therapeutic potential in a human cutaneous squamous cell carcinoma (cSCC) mouse model. In this model, γδT cells were specifically recruited to and maintained in the cSCC xenograft. These tumor-infiltrating cells exhibited an activated, cytotoxic phenotype and demonstrated effective antitumor activity in vivo. Collectively, our findings provide preclinical evidence supporting human skin–resident γδ T cells as a promising immunotherapeutic approach for treating skin cancers such as cSCC.  \ncopyright © 2026 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution license 4.0 (cc BY) .  \nINTRODUCTION  \nγδ are unconventional T lymphocytes that play an important role in tissue immune surveillance (1, 2). They are major histocompatibility complex (MHC) unrestricted, allowing their use in allogeneic cell therapy settings (3, 4), and they express natural cytotoxicity receptors, such as natural killer protein 30 (NKp30), which recognize molecules up-regulated by stressed and malignant cells (5–7). γδ T cells can be rapidly activated and induce apoptosis of the target cells via several mechanisms, includingthe perforin-granzyme pathway, tumor necrosis factor (TNF)–related apoptosis-inducing ligand (TRAIL) and Fas ligand signaling or antibody-dependent cellular cytotoxicity (8–11). γδ T cells exhibit potent antitumor immunity against a wide range of solid and hematopoietic tumors ( 12–14), and tumorinfiltrating γδT cells represent the main favorable prognostic immune cell population among 39 cancer types (15). Together, these features make γδT cells ideal candidates for adoptive cancer immunotherapy.  \nOn the basis of their δ chain expression, human γδ T cells can be subdivided into three main subsets, in which Vδ2+ are predominantly found in the blood whereas Vδ1+ and Vδ3+ are found in epithelial tissues (16, 17) . Vδ1+ γδ T cells account for 80 to 90% of the total γδ T cells skin and gut. These tissue-resident Vδ1+ γδ T cells have garnered attention as potential cancer therapeutics that have natural tissue tropism. Cutaneous squamous cell carcinoma (cSCC) is the second most common epithelial malignancy (18) and although most cases of cSCC are easily cured with surgery or ablation, a subset of these tumors recur, metastasize, and cause death (risk of  \n1department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria. 2institute of Medical Systems Biology, Johannes Kepler University linz, linz, Austria. 3Gammadelta therapeutics ltd, london, UK. 4takeda Pharmaceuticals, Oncology drug discovery Unit, cambridge, MA, USA. 5eB house Austria, Research Program for Molecular therapy of Genodermatoses, department of dermatology and Allergology, University hospital of the Paracelsus Medical University, Salzburg, Austria. 6department of dermatology and venereology, Kepler University hospital linz, linz, Austria","cbCainRTD7exZCoo","https://ap.wps.com/l/cbCainRTD7exZCoo","pdf",2650273,13,"English","# Introduction\n## Rationale for γδ T cells in tissue surveillance and therapy\n## Limitations in skin-cancer preclinical studies\n# Results\n## Human cSCC xenografts recruit proinflammatory γδ T cells","[{\"question\":\"Why are γδ T cells considered promising for cancer immunotherapy?\",\"answer\":\"γδ T cells support tissue immune surveillance, can act in an MHC-unrestricted manner, and rapidly induce cytotoxicity through multiple signaling pathways.\"},{\"question\":\"What challenge limited research on γδ T-cell therapy in skin cancer?\",\"answer\":\"The limited ability to isolate sufficient numbers of γδ T cells from human tissues and the absence of suitable preclinical skin-cancer models restricted investigation.\"},{\"question\":\"What does the xenograft model show about cutaneous γδ T cells in cSCC?\",\"answer\":\"In the cSCC xenograft setting, γδ T cells are recruited and maintained, develop an activated cytotoxic phenotype, and demonstrate effective antitumor activity in vivo.\"}]","Harnessing skin-resident γδ T cells for immunotherapy in cutaneous squamous cell carcinoma | PDF",1790110216,33,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88dac2bfd2f80949925da0c283b52646.webp",983,1250,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/352cc29db7169c3f63faae56c0840439.webp",982,1249,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4678de7172cb840c36f3aad876a95060.webp",981,1248,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0113fb83e623ab77da5ce24c961a723.webp",980,1247]